Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 7,101 shares were traded during mid-day trading, an increase of 92% from the previous session’s volume of 3,696 shares.The stock last traded at $44.03 and had previously closed at $49.75.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on ZLDPF shares. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
View Our Latest Stock Analysis on ZLDPF
Zealand Pharma A/S Price Performance
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The business had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $2.81 million. Equities research analysts expect that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.
About Zealand Pharma A/S
Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.
Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.
See Also
- Five stocks we like better than Zealand Pharma A/S
- The “Duck Stock” Keeps Quietly Making Money for Shareholders
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
